Results 271 to 280 of about 317,690 (321)
ABSTRACT T‐cell lymphoma (TCL) poses a significant challenge in clinical oncology, characterized by its aggressive behavior and resistance to conventional therapies. Despite considerable research efforts, the prognosis for TCL patients remains poor, primarily due to the lack of effective therapeutic strategies that can inhibit tumor progression and ...
Jianru Tian+5 more
wiley +1 more source
Inhibition of Rho-kinase by fasudil contributes to the modulation of the synaptic plasticity response in the rat hippocampus. [PDF]
Babur E, Saray H, Süer C, Dursun N.
europepmc +1 more source
A potent combination of small molecules YFSS (Y27632, Forskolin, SB431542, SP600125) that were screened through a neuronal‐specific promoter–reporter system TUBB3::mCherry effectively induces neuronal‐GBM conversion in vitro and in vivo, unveiling molecular mechanisms that offer a theoretical basis and a potential therapeutic strategy for treating GBM.
Ya'nan Hu+12 more
wiley +1 more source
EFR3A, an Intriguing Gene, and Protein with a Scaffolding Function. [PDF]
Trybus M+3 more
europepmc +1 more source
Scalable Matrigel‐Free Suspension Culture for Generating High‐Quality Human Liver Ductal Organoids
A novel matrigel‐free suspension culture enhances the generation of high‐quality human liver ductal organoids, which shows remarkable efficacy in mice transplantation. ABSTRACT Liver transplantation is currently the sole definitive treatment option for end‐stage liver failure.
Senyi Gong+14 more
wiley +1 more source
Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort. [PDF]
Hu X+23 more
europepmc +1 more source
This article elaborates on the role of NK cells in early pregnancy from multiple perspectives, including molecular mechanisms and therapeutic interventions. It also discusses how NK cell dysfunction contributes to RSA and RIF, aiming to provide insights for future research on NK cell mechanisms and clinical treatment of RSA and RIF.
Defeng Guan+5 more
wiley +1 more source
<i>AKT1</i> and <i>CTNNB1</i> mutations as drivers of paclitaxel resistance in breast cancer cells. [PDF]
Altiparmak-Ulbegi G+2 more
europepmc +1 more source